AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Recruitingn/aAges 50 Years - 85 YearsAllCND Life Sciences
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated ฮฑ-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age 50-85 years old * Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR * Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here." * Willing to participate in all study procedures * Able and willing to provide written informed consent Exclusion Criteria: * Under age 50, Over age 85 * Clinical evidence of severe peripheral vascular disease * Clinically active coronary artery or cerebrovascular disease * Participant is currently on anticoagulant or dual anti-platelet therapy * Alcoholism * Allergic reaction to local anesthesia * History of or increased risk for impaired wound healing, scarring, or keloid formation * Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise * History of other neurodegenerative disorder or evidence of neurological co-pathology * Abnormal DaTscan * Participant is currently receiving treatment with carbidopa-levodopa for PD * Isolated focal tremors (head, voice) * Task-specific tremor (e.g., primary writing tremor) * Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET * Sudden onset and step-wise deterioration * Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

8 sites
CND Clinical Research Center
Scottsdale, United States
Movement Disorders Center of Arizona
Scottsdale, United States
Neurology One
Orlando, United States
University of Kansas Medical Center
Kansas City, United States
Norton Healthcare
Louisville, United States
Quest Research Institute
Farmington Hills, United States
Veracity Neurosciences LLC
Memphis, United States
Vanderbilt University Medical Center
Nashville, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy